A method for manufacturing a fermentation product by culturing a microorganism, the method containing steps (A) to (D): (A) culturing the microorganism with a first culture medium; (B) passing a culture solution containing cultured bacterial cells, raw materials for culture, and the fermentation product through an adsorption tower packed with an adsorbent capable of adsorbing the fermentation product from the culture solution, and then collecting an effluent containing the bacterial cells and the raw materials for culture flowing out from the adsorption tower, wherein a relationship among a size (short diameter) d of the bacterial cell, a pore size D1 of the adsorbent, and a minimum void size D2 between adsorbent particles, D1<d<D2 is satisfied; (C) eluting the fermentation product from the absorbent; and (D) culturing the microorganism with a second culture medium using collected effluent containing the bacterial cells and the raw materials for culture.

The present disclosure provides a novel serine protease variant.

The present invention relates to compositions, methods, uses and kits for treating cancer. The present invention relates to methods for minimising the progression of cancer in a subject, the method comprising administering to the subject therapeutically effective amounts of chymotrypsinogen and trypsinogen, thereby minimising the progression of cancer in the subject. In particular, the methods provide a means for treating cancer by reducing the number of cancer stem cells in the subject.

The invention provides a silk-based biomaterial designed to fabricate a microneedle-like device with controlled degradation rate in planta via tuning material composition and methods of manufacture thereof. The device enables precise access to xylem, phloem, and other plant tissues, thus being capable of serving as delivery tool to release cargo payloads and as sampling tool for analysis of plants fluid.

Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: acid reflux disease, stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. The formulation is also for treating or reducing intolerance of gluten, corn or soy.

A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.

An object of the present invention is to suppress the variation of the elution position of a compound having a charged portion by a preservation liquid, in the purification of the compound, without carrying out the substitution step of the preservation liquid attached to the adsorbent used for the purification and the keeping step. A method for purifying a compound having a charged portion, the method comprising the steps of: preparing a composition containing a compound having a charged portion; preparing a buffer solution comprising a buffering agent and an alcohol, the buffer containing a calcium phosphate compound at least partially, having a buffer capacity in a range of pH 6.0 to pH 8.0, and being soluble in a polar solvent and insoluble in a non-polar solvent; preserving an adsorbent in the buffer solution; adsorbing the compound on the adsorbent by bringing the composition into contact with the adsorbent preserved in the buffer solution; and separating the compound from the adsorbent by gradient elution.

This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concerta®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.

The present invention discloses hydrophobin mimics of formula (I) comprising a protein head group, hydrophilic linker and hydrophobic tail and to a process for synthesis of library of hydrophobin mimics thereof. The hydrophobin mimics of the present invention self-assemble to form protein nanoparticles/nanocontainer either alone or in a specified chemical environment. The hydrophobin mimics (I) of the present invention find application in area of bio-nanotechnology.